Literature DB >> 10070877

Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line.

X F Hu1, A Slater, D Rischin, P Kantharidis, J D Parkin, J Zalcberg.   

Abstract

The effects of 4-demethoxydaunorubicin (idarubicin, IDA) and MX2, a new morpholino-anthracycline, on up-regulation of the MDR1 gene in the low-level multidrug resistant (MDR) cell line CEM/A7R were compared at similar concentrations (IC10, IC50 and IC90) over a short time exposure (4 and 24 h). The chemosensitivity of each drug was determined by a 3-day cell growth inhibition assay. Compared with epirubicin (EPI), IDA and MX2 were 17- and eightfold more effective in the CEM/A7R line respectively. No cross-resistance to 5-FU was seen in the CEM/A7R line. Verapamil (5 microM) and PSC 833 (1 microM), which dramatically reversed resistance to EPI in the CEM/A7R line, had no sensitizing effect on the resistance of this line to MX2, but slightly decreased resistance to IDA. The sensitivity to 5-FU was unchanged by these modulators. The induction of MDR1 mRNA expression by IDA, MX2 and 5-FU was analysed by Northern blotting and semiquantitatively assessed by scanning Northern blots on a phosphorimager. The relative level of MDR1 expression was expressed as a ratio of MDR1 mRNA to the internal RNA control glyceraldehyde-3-phosphate dehydrogenase (GAPDH). IDA, MX2 and 5-FU differentially up-regulated MDR1 mRNA in the CEM/A7R line in a dose-dependent manner. Both IDA and MX2 induced MDR1 expression within 4 h. 5-FU up-regulated MDR1 expression only when drug exposure was prolonged to 24 h. Based on MRK 16 binding, flow cytometric analysis of P-glycoprotein (Pgp) expression paralleled the increase in MDR1 mRNA levels. For the three anthracyclines, the increase in MDR1 expression was stable in cells grown in the absence of drug for more than 3 weeks after drug treatment. The induction of MDR1 expression by 5-FU was transient, associated with a rapid decrease in the increased Pgp levels which returned to baseline 72 h after the removal of 5-FU. This study demonstrates that MDR1 expression can be induced by analogues of anthracyclines not pumped by Pgp, and that this induction appears to be stable despite a 3-week drug-free period.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10070877      PMCID: PMC2362657          DOI: 10.1038/sj.bjc.6690133

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

1.  The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.

Authors:  U Consoli; W Priebe; Y H Ling; R Mahadevia; M Griffin; S Zhao; R Perez-Soler; M Andreeff
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

Review 2.  P-glycoprotein multidrug resistance and cancer.

Authors:  I Bosch; J Croop
Journal:  Biochim Biophys Acta       Date:  1996-10-09

Review 3.  P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation.

Authors:  C Shustik; W Dalton; P Gros
Journal:  Mol Aspects Med       Date:  1995

Review 4.  Cellular resistance to anthracyclines.

Authors:  D Nielsen; C Maare; T Skovsgaard
Journal:  Gen Pharmacol       Date:  1996-03

5.  Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol).

Authors:  C Dumontet; G E Duran; K A Steger; L Beketic-Oreskovic; B I Sikic
Journal:  Cancer Res       Date:  1996-03-01       Impact factor: 12.701

6.  Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.

Authors:  D D Ross; L A Doyle; W Yang; Y Tong; B Cornblatt
Journal:  Biochem Pharmacol       Date:  1995-11-09       Impact factor: 5.858

Review 7.  Regulation of multidrug resistance through the cAMP and EGF signalling pathways.

Authors:  C Rohlff; R I Glazer
Journal:  Cell Signal       Date:  1995-07       Impact factor: 4.315

8.  Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line.

Authors:  X F Hu; A Slater; D M Wall; J D Parkin; P Kantharidis; J R Zalcberg
Journal:  Clin Cancer Res       Date:  1996-04       Impact factor: 12.531

9.  Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia.

Authors:  G Del Poeta; R Stasi; G Aronica; A Venditti; M C Cox; A Bruno; F Buccisano; M Masi; M Tribalto; S Amadori; G Papa
Journal:  Blood       Date:  1996-03-01       Impact factor: 22.113

10.  Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.

Authors:  L Beketic-Oreskovic; G E Durán; K G Chen; C Dumontet; B I Sikic
Journal:  J Natl Cancer Inst       Date:  1995-11-01       Impact factor: 13.506

View more
  4 in total

1.  Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression.

Authors:  Osamu Kikuchi; Shinya Ohashi; Yukie Nakai; Shunsaku Nakagawa; Kazuaki Matsuoka; Takashi Kobunai; Teiji Takechi; Yusuke Amanuma; Masahiro Yoshioka; Tomomi Ida; Yoshihiro Yamamoto; Yasushi Okuno; Shin'ichi Miyamoto; Hiroshi Nakagawa; Kazuo Matsubara; Tsutomu Chiba; Manabu Muto
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

2.  Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells.

Authors:  Valérie Gouazé-Andersson; Jing Y Yu; Adam J Kreitenberg; Alicja Bielawska; Armando E Giuliano; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2007-11-09

3.  Cyclosporine A enables vincristine-induced apoptosis during reversal of multidrug resistance phenotype in chronic myeloid leukemia cells.

Authors:  Paloma Silva de Souza; Flavia da Cunha Vasconcelos; Luis Felipe R Silva; Raquel Ciuvalschi Maia
Journal:  Tumour Biol       Date:  2012-01-31

4.  Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways.

Authors:  X F Hu; J Li; E Yang; S Vandervalk; P X Xing
Journal:  Br J Cancer       Date:  2007-03-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.